uniQure N.V. APIC, Share-based Payment Arrangement, Increase for Cost Recognition
uniQure N.V. (QURE) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $5.09 million for the 3-month period ending 2026-03-31, per its 10-Q filed 2026-05-05.
Financial Statements
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-05-05
- uniQure N.V. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $5.09M, a 15.42% increase year-over-year.
- uniQure N.V. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-12-31 was $4.66M, a 1.81% decline year-over-year.
- uniQure N.V. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $3.52M, a 2.44% increase year-over-year.
- uniQure N.V. apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $5.08M, a 26.10% decline year-over-year.
- uniQure N.V. apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $17.68M, a 20.57% decline from fiscal 2024.
- uniQure N.V. apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $22.26M, a 36.57% decline from fiscal 2023.
- uniQure N.V. apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $35.09M, a 2.60% increase from fiscal 2022.
- uniQure N.V. apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $34.20M, a 33.43% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-03-31 | $5.09M 10-Q · filed 2026-05-05 | $9.75M derived: sum of 2 quarters · filed 2026-05-05 | $13.28M derived: sum of 3 quarters · filed 2026-05-05 | $18.36M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | $4.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $8.19M derived: sum of 2 quarters · filed 2026-03-02 | $13.27M derived: sum of 3 quarters · filed 2026-03-02 | $17.68M 10-K · filed 2026-03-02 |
| 2025-09-30 | $3.52M 10-Q · filed 2025-11-10 | $8.61M derived: sum of 2 quarters · filed 2025-11-10 | $13.02M 10-Q · filed 2025-11-10 | $17.77M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-30 | $5.08M 10-Q · filed 2025-07-29 | $9.49M 10-Q · filed 2025-07-29 | $14.24M derived: sum of 3 quarters · filed 2026-05-05 | $17.68M derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-31 | $4.41M 10-Q · filed 2026-05-05 | $9.16M derived: sum of 2 quarters · filed 2026-05-05 | $12.60M derived: sum of 3 quarters · filed 2026-05-05 | $19.48M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $4.75M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $8.19M derived: sum of 2 quarters · filed 2026-03-02 | $15.07M derived: sum of 3 quarters · filed 2026-03-02 | $22.26M 10-K · filed 2026-03-02 |
| 2024-09-30 | $3.44M 10-Q · filed 2025-11-10 | $10.32M derived: sum of 2 quarters · filed 2025-11-10 | $17.51M 10-Q · filed 2025-11-10 | $24.55M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $6.88M 10-Q · filed 2025-07-29 | $14.07M 10-Q · filed 2025-07-29 | $21.11M derived: sum of 3 quarters · filed 2026-03-02 | $32.21M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $7.19M 10-Q · filed 2025-05-09 | $14.23M derived: sum of 2 quarters · filed 2026-03-02 | $25.33M derived: sum of 3 quarters · filed 2026-03-02 | $34.22M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $7.04M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $18.14M derived: sum of 2 quarters · filed 2026-03-02 | $27.03M derived: sum of 3 quarters · filed 2026-03-02 | $35.09M 10-K · filed 2026-03-02 |
| 2023-09-30 | $11.10M 10-Q · filed 2024-11-05 | $19.99M derived: sum of 2 quarters · filed 2024-11-05 | $28.05M 10-Q · filed 2024-11-05 | $39.97M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $8.89M 10-Q · filed 2024-08-01 | $16.95M 10-Q · filed 2024-08-01 | $28.87M derived: sum of 3 quarters · filed 2025-02-27 | $36.48M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $8.06M 10-Q · filed 2024-05-07 | $19.98M derived: sum of 2 quarters · filed 2025-02-27 | $27.58M derived: sum of 3 quarters · filed 2025-02-27 | $35.40M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $11.91M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $19.52M derived: sum of 2 quarters · filed 2025-02-27 | $27.34M derived: sum of 3 quarters · filed 2025-02-27 | $34.20M 10-K · filed 2025-02-27 |
| 2022-09-30 | $7.61M 10-Q · filed 2023-11-07 | $15.42M derived: sum of 2 quarters · filed 2023-11-07 | $22.29M 10-Q · filed 2023-11-07 | $29.18M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $7.81M 10-Q · filed 2023-08-01 | $14.68M 10-Q · filed 2023-08-01 | $21.57M derived: sum of 3 quarters · filed 2024-02-28 | $27.52M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $6.87M 10-Q · filed 2023-05-09 | $13.76M derived: sum of 2 quarters · filed 2024-02-28 | $19.71M derived: sum of 3 quarters · filed 2024-02-28 | $26.74M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $6.89M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $12.84M derived: sum of 2 quarters · filed 2024-02-28 | $19.87M derived: sum of 3 quarters · filed 2024-02-28 | $25.64M 10-K · filed 2024-02-28 |
| 2021-09-30 | $5.96M 10-Q · filed 2022-11-02 | $12.99M derived: sum of 2 quarters · filed 2022-11-02 | $18.75M 10-Q · filed 2022-11-02 | $24.13M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $7.03M 10-Q · filed 2022-08-08 | $12.79M 10-Q · filed 2022-08-08 | $18.17M derived: sum of 3 quarters · filed 2023-02-27 | $24.55M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $5.76M 10-Q · filed 2022-05-02 | $11.14M derived: sum of 2 quarters · filed 2023-02-27 | $17.51M derived: sum of 3 quarters · filed 2023-02-27 | $23.24M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $5.38M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $11.75M derived: sum of 2 quarters · filed 2023-02-27 | $17.48M derived: sum of 3 quarters · filed 2023-02-27 | $21.83M 10-K · filed 2023-02-27 |
| 2020-09-30 | $6.37M 10-Q · filed 2021-10-25 | $12.10M derived: sum of 2 quarters · filed 2021-10-25 | $16.45M 10-Q · filed 2021-10-25 | $21.22M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-06-30 | $5.72M 10-Q · filed 2021-07-26 | $10.08M 10-Q · filed 2021-07-26 | $14.85M derived: sum of 3 quarters · filed 2022-02-25 | $18.73M derived: sum of 4 quarters · filed 2022-02-25 |
| 2020-03-31 | $4.36M 10-Q · filed 2021-05-10 | $9.13M derived: sum of 2 quarters · filed 2022-02-25 | $13.00M derived: sum of 3 quarters · filed 2022-02-25 | $17.59M derived: sum of 4 quarters · filed 2022-02-25 |
| 2019-12-31 | $4.77M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $8.65M derived: sum of 2 quarters · filed 2022-02-25 | $13.24M derived: sum of 3 quarters · filed 2022-02-25 | $17.53M 10-K · filed 2022-02-25 |
| 2019-09-30 | $3.88M 10-Q · filed 2020-10-27 | $8.47M derived: sum of 2 quarters · filed 2020-10-27 | $12.76M 10-Q · filed 2020-10-27 | $16.12M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-06-30 | $4.59M 10-Q · filed 2020-07-30 | $8.89M 10-Q · filed 2020-07-30 | $12.24M derived: sum of 3 quarters · filed 2021-03-01 | $14.86M derived: sum of 4 quarters · filed 2021-03-01 |
| 2019-03-31 | $4.29M 10-Q · filed 2020-04-29 | $7.65M derived: sum of 2 quarters · filed 2021-03-01 | $10.27M derived: sum of 3 quarters · filed 2021-03-01 | $12.47M derived: sum of 4 quarters · filed 2021-03-01 |
| 2018-12-31 | $3.36M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $5.98M derived: sum of 2 quarters · filed 2021-03-01 | $8.18M derived: sum of 3 quarters · filed 2021-03-01 | $10.71M 10-K · filed 2021-03-01 |
| 2018-09-30 | $2.62M 10-Q · filed 2019-10-28 | $4.83M derived: sum of 2 quarters · filed 2019-10-28 | $7.35M 10-Q · filed 2019-10-28 | $11.65M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $2.21M 10-Q · filed 2019-07-29 | $4.73M 10-Q · filed 2019-07-29 | $9.03M derived: sum of 3 quarters · filed 2020-03-02 | $11.48M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $2.53M 10-Q · filed 2019-04-29 | $6.83M derived: sum of 2 quarters · filed 2020-03-02 | $9.28M derived: sum of 3 quarters · filed 2020-03-02 | $11.20M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $4.30M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-02 | $6.75M derived: sum of 2 quarters · filed 2020-03-02 | $8.68M derived: sum of 3 quarters · filed 2020-03-02 | $10.28M 10-K · filed 2020-03-02 |
| 2017-09-30 | $2.45M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-01 | $4.37M derived: sum of 2 quarters · filed 2017-11-01 | $5.98M 10-Q · filed 2017-11-01 | |
| 2017-06-30 | $1.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $3.53M 10-Q · filed 2017-08-08 | ||
| 2017-03-31 | $1.60M 10-Q · filed 2017-05-09 | |||
| 2016-12-31 | $6.21M 10-K · filed 2019-02-28 | |||
| 2015-12-31 | $11.62M 10-K · filed 2018-03-14 | |||
| 2014-12-31 | $8.40M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |